Lyrica

Lyrica looking grim: Pfizer blockbuster's market share crumbles under generic attack
Lyrica looking grim: Pfizer blockbuster's market share crumbles under generic attack
Fierce Pharma
Pfizer
patents
Lyrica
generics
Flag link:
Lyrica Patent Expiration Ushers In 9 Generic Competitors
Lyrica Patent Expiration Ushers In 9 Generic Competitors
Xtalks
Pfizer
Lyrica
patents
generics
Alembic Pharmaceuticals
Alkem Laboratories
Amneal
Dr Reddy's
InvaGen
MGN Laboratories
Rising Pharmaceuticals
Sciegen Pharmaceuticals
Teva Pharmaceutical
Flag link:
Lyrica generics roll: Pfizer blockbuster finally hits patent cliff
Lyrica generics roll: Pfizer blockbuster finally hits patent cliff
Fierce Pharma
Pfizer
Lyrica
FDA
patents
Flag link:
Pfizer's About to Enter a Sales Slump
Pfizer's About to Enter a Sales Slump
Motley Fool
Pfizer
Lyrica
patents
Flag link:
Top 10 drugs losing exclusivity in 2019
Top 10 drugs losing exclusivity in 2019
Fierce Pharma
market exclusivity
patents
Rituxan
Lyrica
Herceptin
Avastin
Epclusa
Harvoni
Pfizer
Roche
Gilead Sciences
Amgen
GSK
Allergan
Individor
Flag link:
Powerful Democrat wants Pfizer to explain price hikes for Lyrica, its nerve pain drug
Powerful Democrat wants Pfizer to explain price hikes for Lyrica, its nerve pain drug
Stat
Senate
drug pricing
Pfizer
Lyrica
Flag link:
Pfizer wins blockbuster Lyrica patent extension to safeguard sales till June
Pfizer wins blockbuster Lyrica patent extension to safeguard sales till June
Fierce Pharma
Pfizer
Lyrica
patents
FDA
pediatric exclusivity
Flag link:
Pfizer falls short in U.K. patent appeal for blockbuster Lyrica
Pfizer falls short in U.K. patent appeal for blockbuster Lyrica
Fierce Pharma
Pfizer
patents
UK
Lyrica
Flag link:
Pfizer's LYRICA Meets Primary Endpoint in Phase III Trial in Pediatric Epilepsy
Pfizer's LYRICA Meets Primary Endpoint in Phase III Trial in Pediatric Epilepsy
CP Wire
Pfizer
Lyrica
pediatric epilepsy
pediatrics
Flag link:
Pfizer's LYRICA Meets Primary Endpoint in Phase III Trial in Pediatric Epilepsy
Pfizer
Lyrica
pediatric epilepsy
Flag link:
Better together? AbbVie’s Humira and Pfizer’s Lyrica again outspend other brands
Better together? AbbVie’s Humira and Pfizer’s Lyrica again outspend other brands
Fierce Pharma
AbbVie
Pfizer
television ads
DTC ads
Humira
Lyrica
Flag link:
Pfizer's Ibrance hits the TV ad-spending top 10, joining stalwarts Humira and Lyrica
Pfizer's Ibrance hits the TV ad-spending top 10, joining stalwarts Humira and Lyrica
Fierce Pharma
Pfizer
Ibrance
television ads
Humira
AbbVie
DTC advertising
Lyrica
Flag link:
Neurontin prescriptions surge amid opioid crisis
Neurontin prescriptions surge amid opioid crisis
Reuters
Neurontin
opioid crisis
Lyrica
painkillers
Flag link:
Humira back on top of TV spending list for October, ahead of Lyrica and Victoza
Humira back on top of TV spending list for October, ahead of Lyrica and Victoza
Fierce Pharma
Humira
Lyrica
Victoza
AbbVie
Pfizer
Novo Nordisk
television ads
DTC ads
Flag link:
With a year left before generics hit, Pfizer nabs FDA approval for new-and-improved Lyrica
With a year left before generics hit, Pfizer nabs FDA approval for new-and-improved Lyrica
Fierce Pharma
Pfizer
FDA
Lyrica
generics
Lyrica CR
shingles
diabetic peripheral neuropathy
Flag link:
Pfizer's Lyrica takes pharma TV spending crown from AbbVie's Humira for September
Pfizer's Lyrica takes pharma TV spending crown from AbbVie's Humira for September
Fierce Pharma
Pfizer
Lyrica
AbbVie
Humira
drug ads
television ads
Flag link:
With Viagra and Lyrica fading, analysts downgrade Pfizer due to mounting challenges
With Viagra and Lyrica fading, analysts downgrade Pfizer due to mounting challenges
Fierce Pharma
Pfizer
Viagra
Lyrica
patents
Flag link:
Viagra, Lyrica among 91 meds to get June price hikes at Pfizer: FT
Viagra, Lyrica among 91 meds to get June price hikes at Pfizer: FT
Fierce Pharma
Pfizer
drug pricing
Lyrica
Viagra
Flag link:
Pfizer’s Lyrica Ineffective for Sciatica Pain
Pfizer’s Lyrica Ineffective for Sciatica Pain
Investopedia
Pfizer
Lyrica
sciatica
Flag link:
The 3 Biggest Risks for Pfizer in 2017
The 3 Biggest Risks for Pfizer in 2017
Motley Fool
Pfizer
Xtandi
competition
patents
Lyrica
Celebrex
Flag link:

Pages